AQR Arbitrage’s Jasper Therapeutics JSPR Stock Holding History

AQR Arbitrage’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,852	Closed	-$980K	–	1183
2021 Q2	$980K	Buy	9,852 +6,701	+213%	+$666K	0.03%	494
2021 Q1	$313K	Sell	3,151 -1,849	-37%	-$188K	0.01%	699
2020 Q4	$501K	Hold	5,000	–	–	0.02%	663
2020 Q3	$496K	Sell	5,000 -23,125	-82%	-$2.31M	0.02%	428
2020 Q2	$2.81M	Hold	28,125	–	–	0.13%	167
2020 Q1	$2.69M	Buy	+28,125	New	+$2.75M	0.09%	205

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AQR Arbitrage's JSPR Position: Q3 2021 in Review

AQR Arbitrage sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 9,852 shares — an estimated $980K sold.

AQR Arbitrage first reported a position in JSPR in Q1 2020 and held it in 6 quarters. The position peaked at $2.81M in Q2 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

AQR Arbitrage reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
AQR Arbitrage sold 9,852 Jasper Therapeutics shares in Q3 2021, an estimated $980K.
AQR Arbitrage first reported a position in Jasper Therapeutics in Q1 2020 and held it in 6 quarters.
AQR Arbitrage's Jasper Therapeutics position peaked at $2.81M in Q2 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on AQR Arbitrage's 13F filing for Q3 2021, filed 15 Nov 2021.